|
1
|
Robinson GW, Orr BA, Wu G, Gururangan S,
Lin T, Qaddoumi I, Packer RJ, Goldman S, Prados MD, Desjardins A,
et al: Vismodegib exerts targeted efficacy against recurrent sonic
hedgehog-subgroup medulloblastoma: Results from phase ii pediatric
brain tumor consortium studies PBTC-025B and PBTC-032. J Clin
Oncol. 33:2646–2654. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Deutsch M, Thomas PR, Krischer J, Boyett
JM, Albright L, Aronin P, Langston J, Allen JC, Packer RJ, Linggood
R, et al: Results of a prospective randomized trial comparing
standard dose neuraxis irradiation (3,600 cGy/20) with reduced
neuraxis irradiation (2,340 cGy/13) in patients with low-stage
medulloblastoma. A combined children's cancer group-pediatric
oncology group study. Pediatr Neurosurg. 24:167–177. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Allen J, Donahue B, Mehta M, Miller DC,
Rorke LB, Jakacki R, Robertson P, Sposto R, Holmes E, Vezina G, et
al: A phase II study of preradiotherapy chemotherapy followed by
hyperfractionated radiotherapy for newly diagnosed high-risk
medulloblastoma/primitive neuroectodermal tumor: A report from the
children's oncology group (CCG 9931). Int J Radiat Oncol Biol Phys.
74:1006–1011. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cefalo G, Massimino M, Ruggiero A, Barone
G, Ridola V, Spreafico F, Potepan P, Abate ME, Mascarin M, Garrè
ML, et al: Temozolomide is an active agent in children with
recurrent medulloblastoma/primitive neuroectodermal tumor: An
Italian multi-institutional phase II trial. Neuro Oncol.
16:748–753. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dhall G, Grodman H, Ji L, Gardner S,
Dunkel IJ, McCowage GB, Diez B, Allen JC, Gopalan A, Cornelius AS,
et al: Outcome of children less than three years old at diagnosis
with non-metastatic medulloblastoma treated with chemotherapy on
the ‘Head Start’ I and II protocols. Pediatr Blood Cancer.
50:1169–1175. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ito T, Kohashi K, Yamada Y, Maekawa A,
Kuda M, Furue M and Oda Y: Prognostic significance of Forkhead box
M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in
melanoma. Histopathology. 69:63–71. 2015. View Article : Google Scholar
|
|
7
|
Dai J, Yang L, Wang J, Xiao Y and Ruan Q:
Prognostic value of FOXM1 in patients with malignant solid tumor: A
meta-analysis and system review. Dis Markers. 2015:3524782015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao F and Lam EW: Role of the forkhead
transcription factor FOXO-FOXM1 axis in cancer and drug resistance.
Front Med. 6:376–380. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Quan M, Wang P, Cui J, Gao Y and Xie K:
The roles of FOXM1 in pancreatic stem cells and carcinogenesis. Mol
Cancer. 12:1592013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi M, Cui J and Xie K: Signaling of
miRNAs-FOXM1 in cancer and potential targeted therapy. Curr Drug
Targets. 14:1192–1202. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chambers M, Kirkpatrick G, Evans M, Gorski
G, Foster S and Borghaei RC: IL-4 inhibition of IL-1 induced Matrix
metalloproteinase-3 (MMP-3) expression in human fibroblasts
involves decreased AP-1 activation via negative crosstalk involving
of Jun N-terminal kinase (JNK). Exp Cell Res. 319:1398–1408. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Uluckan O, Guinea-Viniegra J, Jimenez M
and Wagner EF: Signalling in inflammatory skin disease by AP-1
(Fos/Jun). Clin Exp Rheumatol. 33 4 Suppl 92:S44–S49.
2015.PubMed/NCBI
|
|
13
|
Wang WX, Sun ZH, Chen HM, Xu BN and Wang
FY: Role and mechanism of Sophoridine on proliferation inhibition
in human glioma U87MG cell line. Int J Clin Exp Med. 8:464–471.
2015.PubMed/NCBI
|
|
14
|
Zhang B, Liu ZY, Li YY, Luo Y, Liu ML,
Dong HY, Wang YX, Liu Y, Zhao PT, Jin FG and Li ZC:
Antiinflammatory effects of matrine in LPS-induced acute lung
injury in mice. Eur J Pharm Sci. 44:573–579. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liou CJ, Lai YR, Chen YL, Chang YH, Li ZY
and Huang WC: Matrine attenuates COX-2 and ICAM-1 Expressions in
human lung epithelial cells and prevents acute lung injury in
LPS-induced mice. Mediators Inflamm. 2016:36304852016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gessi M, von Bueren AO, Rutkowski S and
Pietsch T: p53 expression predicts dismal outcome for
medulloblastoma patients with metastatic disease. J Neurooncol.
106:135–141. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Camara-Costa H, Resch A, Kieffer V,
Lalande C, Poggi G, Kennedy C, Bull K, Calaminus G, Grill J, Doz F,
et al: Neuropsychological outcome of children treated for standard
risk Medulloblastoma in the PNET4 european randomized controlled
trial of hyperfractionated versus standard radiation therapy and
maintenance chemotherapy. Int J Radiat Oncol Biol Phys. 92:978–985.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Palmer SL, Leigh L, Ellison SC,
Onar-Thomas A, Wu S, Qaddoumi I, Armstrong GT, Wright K, Wetmore C,
Broniscer A and Gajjar A: Feasibility and efficacy of a
computer-based intervention aimed at preventing reading decoding
deficits among children undergoing active treatment for
medulloblastoma: Results of a randomized trial. J Pediatr Psychol.
39:450–458. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang HQ, Jin JJ and Wang J: Matrine
induces mitochondrial apoptosis in cisplatin-resistant non-small
cell lung cancer cells via suppression of β-catenin/survivin
signaling. Oncol Rep. 33:2561–2566. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arora R, Yates C, Gary BD, McClellan S,
Tan M, Xi Y, Reed E, Piazza GA, Owen LB and Dean-Colomb W:
Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation,
induce apoptosis and reverse epithelial to mesenchymal transition
in breast cancer. PLoS One. 9:e983702014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Arslan S, Korkmaz Ö, Özbilüm N and Berkan
Ö: Association between NF-κBI and NF-κB BIA polymorphisms and
coronary artery disease. Biomed Rep. 3:736–740. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qian Y, Guan T, Huang M, Cao L, Li Y,
Cheng H, Jin H and Yu D: Neuroprotection by the soy isoflavone,
genistein, via inhibition of mitochondria-dependent apoptosis
pathways and reactive oxygen induced-NF-κB activation in a cerebral
ischemia mouse model. Neurochem Int. 60:759–767. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Q, Lai Y, Wang C, Xu G, He Z, Shang X,
Sun Y, Zhang F, Liu L and Huang H: Matrine inhibits the
proliferation, invasion and migration of castration-resistant
prostate cancer cells through regulation of the NF-κB signaling
pathway. Oncol Rep. 35:375–381. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kasemeier-Kulesa JC, Morrison JA, Lefcort
F and Kulesa PM: TrkB/BDNF signalling patterns the sympathetic
nervous system. Nat Commun. 6:82812015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ghiglieri V, Sgobio C, Patassini S,
Bagetta V, Fejtova A, Giampà C, Marinucci S, Heyden A, Gundelfinger
ED, Fusco FR, et al: TrkB/BDNF-dependent striatal plasticity and
behavior in a genetic model of epilepsy: Modulation by valproic
acid. Neuropsychopharmacology. 35:1531–1540. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Turner BA, Sparrow J, Cai B, Monroe J,
Mikawa T and Hempstead BL: TrkB/BDNF signaling regulates
photoreceptor progenitor cell fate decisions. Dev Biol.
299:455–465. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Odate S, Nakamura K, Onishi H, Kojima M,
Uchiyama A, Nakano K, Kato M, Tanaka M and Katano M: TrkB/BDNF
signaling pathway is a potential therapeutic target for pulmonary
large cell neuroendocrine carcinoma. Lung Cancer. 79:205–214. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kan QC, Lv P, Zhang XJ, Xu YM, Zhang GX
and Zhu L: Matrine protects neuro-axon from CNS
inflammation-induced injury. Exp Mol Pathol. 98:124–130. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu L, Ning H, Gu L, Wang Q, Lu W, Peng H,
Cui W, Ying B, Ross CR, Wilson GM, et al: Tristetraprolin induces
cell cycle arrest in breast tumor cells through targeting
AP-1/c-Jun and NF-κB pathway. Oncotarget. 6:41679–41691. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kuang H, Hua X, Zhou J and Yang R:
Resolvin D1 and E1 alleviate the progress of hepatitis toward liver
cancer in long-term concanavalin A-induced mice through inhibition
of NF-κB activity. Oncol Rep. 35:307–317. 2016. View Article : Google Scholar : PubMed/NCBI
|
